ArticleFrontiers in pediatrics2025
Virological failure in a pediatric cohort on a dolutegravir based regimen: a retrospective study in northwest Ethiopia, 2017-2023.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Impact of Dolutegravir-Based Antiretroviral Therapy on Viral Load Suppression and Uptake of DTG-Based Regimen Among Pediatric HIV Patients in Africa: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS CarePooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite the fact that antiretroviral therapy (ART) has reduced HIV/AIDS-related morbidity and mortality, pediatrics treatment failure remains a global concern. As a result, this study set out prudently to determine the prevalence of virologic failure and its predictors among children and adolescents on a Dolutegravir (DTG)-based antiretroviral regimen. Methods: A hospital-based retrospective cross-sectional study was conducted on children and adolescents on ART at Debre Tabor Comprehensive Specialized Hospital in Northwest Ethiopia from February-2017 to September-2023. Study participants were selected purposively. Data was collected using a semi-structured questionnaire and a data abstraction tool. Bivariate and multivariate logistic regression analyses were fitted to determine the linked factors. A Results: Among the 359 children and adolescents included in this study, 38 (10.58%) had developed virological failure. The odds of virological failure among children and adolescents were found to be increased by the age of the child <10 years (AOR = 4.41; 95% CI: 2.60-7.47), the care taker being a guardian or neighbor of patient (AOR = 2.03; 95% CI: 1.15-4.73), both parents passing away (AOR = 1.29; 95% CI: 0.12-2.68), CD4 counts ≤200 cells/µL (AOR = 4.3; 95% CI: 1.32-5.9), being infected with OIs (AOR = 2.03; 95% CI: 1.38-3.55), poor adherence status (AOR = 1.37: 95% CI: 1.12-3.11), adverse drug reaction (AOR = 1.75: 95% CI: 1.02-4.97), and anemic (AOR = 1.70: 95% CI: 1.03-5.15.04). Conclusion: Despite potent DTG-based ARTs being introduced, virologic failure remains a concern in the study area. Special consideration should be directed towards children under the age of 10 years who are in the care of a guardian or neighbors, have lost both parents, are infected with opportunistic infections, have a poor adherence status, are experiencing adverse drug reactions, and anemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.